I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Pediatria, Neonatologia, Medicina dell’Adolescenza
e Neuropsichiatria Infantile
Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532
Minerva Pediatrica 2014 Ottobre;66(5):363-7
Pidotimod may prevent recurrent respiratory infections in children
Licari A., De Amici M., Nigrisoli S., Marseglia A., Caimmi S., Artusio L., Marseglia G. L. ✉
Immuno‑Pneumo‑Allergy Unit, Department of Pediatrics, University of Pavia, Fondazione IRCCS San Matteo, Pavia, Italy
AIM: Recurrent respiratory infections (RRI) constitute a social problem for both the pharmaco-economic impact and the burden for the family. Pidotimod is a synthetic immunostimulant. The aim of this study was to evaluate the effects of pidotimod on RRI prevention in children.
METHODS: Globally, 100 children (49 males, mean age 4.7±1.2 years) with RRI were enrolled in the study. At baseline, children were randomly assigned to the treatment with pidotimod 400 mg/die or not for two months. Children were visited at baseline, after 30 (T1) and 60 (T2) days, and at follow-up (120 days; T3). Number of children with upper and lower airways symptoms, medications use, school attendance, and paediatric visits for RRI were evaluated.
RESULTS: Pidotimod treatment was able of significantly reducing the number of children with upper and lower airways symptoms, and medications use, increasing school attendance, and reducing pediatric visits for RRI.
CONCLUSION: This study provided the evidence that pidotimod may be able of preventing RRI in children.